Loading…
Symbiotec Pharmalab (SYMBIOTEC)₹1,555−2.70%Pharmaceuticals
At the end of the Sep 2026 quarter, Symbiotec Pharmalab's shareholders were: promoters 33.26%, FIIs 21.06%, DIIs 27.49%, public 18.19%. 0.00% of promoter shares were pledged. It had 4,27,785 shareholders.
As of · Company filings (shareholding pattern)
| Sep 2026 | |
|---|---|
| Promoters | 33.26% |
| FIIs | 21.06% |
| DIIs | 27.49% |
| Public | 18.19% |
| Promoter shares pledged | 0.00% |
| Number of shareholders | 4,27,785 |
| Holder | Category | Sep 2026 | Change (pp) |
|---|---|---|---|
| Satwani Holdings Llp | Promoter | 15.27% | — |
| Rosewood Investments | FII | 14.09% | — |
| Business Excellence Trust Iii - India Business Excellence Fund Iii | DII | 10.26% | — |
| Anil Satwani | Promoter | 4.36% | — |
| Kashish Satwani | Promoter | 4.29% | — |
| Arjun Anil Satwani Family Trust | Promoter | 3.44% | — |
| Krishna Anil Satwani Family Trust | Promoter | 3.39% | — |
| Valuequest Founders Conviction Lvf | DII | 2.93% | — |
| Think India Opportunities Master Fund Lp | FII | 2.77% | — |
| Sushil Satwani | Promoter | 1.93% | — |
| Dymon Asia Multi-Strategy Investment (Singapore) Pte. Ltd | FII | 1.59% | — |
| Icici Prudential Smallcap Fund | DII | 1.02% | — |
| Kashish And Anil Satwani Family Trust | Promoter | 0.54% | — |
| Sunil Satwani | Promoter | 0.02% | — |
| Swati Sachdev | Promoter | 0.02% | — |
Promoters held 33.26% of Symbiotec Pharmalab at the end of the Sep 2026 quarter.
In the Sep 2026 quarter, foreign institutional investors (FIIs) held 21.06% and domestic institutions (DIIs) held 27.49%.
No. The Sep 2026 filing shows no pledged promoter shares.
Symbiotec Pharmalab had 4,27,785 shareholders at the end of the Sep 2026 quarter.
Rosewood Investments (FII) held 14.09% at the end of the Sep 2026 quarter, the largest named holding outside the promoter group.